A3P Biomedical shares
Unlisted company
A3P Biomedical develops and commercialises Stockholm3, a blood-based diagnostic test for the early detection and risk assessment of aggressive prostate cancer. The test combines protein biomarkers, genetic markers and clinical data in an algorithm that provides a more accurate assessment than the traditional PSA test. Stockholm3 has been validated in clinical studies involving more than 90,000 men and published in leading medical journals such as The Lancet Oncology, Journal of Clinical Oncology and European Urology.
How the company makes money
The company generates revenue through sales of the Stockholm3 test to hospitals, clinics and healthcare providers. The test is offered in both public and private healthcare across a growing number of markets, with a focus on the Nordics and Europe, as well as expansion into the US market. The business model is based on integrating Stockholm3 into existing care pathways as a diagnostic tool, with revenue driven by test volumes.
The research behind the test
A3P Biomedical was founded based on research conducted at Karolinska Institutet. Co-founder Henrik Grönberg, Professor of Cancer Epidemiology at Karolinska Institutet, has played a central role in developing the Stockholm3 test together with his research team.
Advantages over PSA
Detects 41–89% more aggressive cases
Reduces overdiagnosis by 37–52%
Fewer unnecessary biopsies and MRI scans
Effective even at low PSA levels
Revenue and markets
Sales of the test to healthcare providers
Public and private healthcare
The Nordics, Europe and the US
Financial performance
Published 24 September 2026Published figures from the company’s own reports. Amounts in MSEK · change from the previous year
- Cash and bank 2025-12-31
- 22MSEK
- Burn rate
- 5.8MSEK/mo
- Runway
- 4mo
- Equity ratio
- 84.2%
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Net sales | 18(+18.2 %) | 16(+51.3 %) | 10(-48.4 %) | 20(-1.6 %) |
| Revenue growth | 18.2%(-33.1 pp) | 51.3%(+99.7 pp) | -48.4%(-46.8 pp) | -1.6% |
| EBITDA | -77 | -74 | -86 | -63 |
| EBIT | -83 | -79 | -92 | -67 |
| Net income | -79 | -71 | -82 | -65 |
| Equity | 156(-31.3 %) | 227(-23.5 %) | 297(-21.5 %) | 379(+503.9 %) |
| Cash and bank | 22(-12.5 %) | 25(-74.2 %) | 96(+114.8 %) | 44(-24.9 %) |
| Operating cash flow | -69 | -65 | -70 | -63 |
| Equity ratio | 84.2%(-4.5 pp) | 88.7%(-3 pp) | 91.7%(-1.4 pp) | 93.1%(+26.2 pp) |
Documents and reports
4New share issues
Latest 1An overview of the company’s capital raising.
| Date | Capital raised | Valuation |
|---|---|---|
| SEK 400m | SEK 1bn |
Questions about A3P Biomedical
Is A3P Biomedical publicly listed?
A3P Biomedical AB is a public limited company, but its shares are not publicly listed, and the company has not completed an IPO. Instead, its shares are traded on the unlisted market, which means that they are not traded on a regulated stock exchange.
What does A3P Biomedical do?
A3P Biomedical is a Swedish medical technology company that develops and commercializes advanced diagnostics for prostate cancer. The company is known for the Stockholm3 test, which combines clinical data, genetic markers, and protein biomarkers to provide a more accurate assessment of aggressive prostate cancer than traditional PSA tests.
Can I buy shares in A3P Biomedical?
Yes, it is possible to buy shares in A3P Biomedical through trading in unlisted shares, provided that there are sellers. Through Eqvor, you can place a buy order and be matched with sellers in the unlisted market.
How do I sell shares in A3P Biomedical?
If you own shares in A3P Biomedical, you can place a sell order through Eqvor and be matched with buyers. Once the transaction has been completed, the shares are delivered in accordance with the company’s Euroclear-connected custody structure.
Is A3P Biomedical affiliated with Euroclear?
Yes, A3P Biomedical is affiliated with Euroclear. This means that the shares are managed in the Swedish securities system and can be delivered to a custody account with any bank or securities firm once the transaction has been completed.
Can I hold A3P Biomedical shares with Avanza or Nordnet?
Yes, since A3P Biomedical is affiliated with Euroclear, the shares can normally be held in a securities account with, for example, Avanza or Nordnet, provided that the bank or online broker supports the custody of this type of unlisted share.
Does A3P Biomedical have post-transfer purchase rights or pre-emption clauses?
No, according to the company information, A3P Biomedical has neither post-transfer purchase rights nor pre-emption rights. This means that share transfers normally do not need to be offered to existing shareholders before being sold to an external buyer.
At what price is the A3P Biomedical share traded?
A3P Biomedical is not listed on a stock exchange and therefore has no official share price on a regulated marketplace. Instead, the price is determined by supply and demand among buyers and sellers in the private market.
Has A3P Biomedical carried out any share issues?
Yes, A3P Biomedical has raised capital. The company's Capital raised is stated as SEK 535.3 million, indicating how much capital the company has raised through previous financing rounds.
When will A3P Biomedical be listed on the stock exchange?
There is currently no public timetable for a stock exchange listing of A3P Biomedical. We therefore do not know when the company may be listed or whether it will conduct an IPO.
What are the risks of investing in A3P Biomedical?
Investing in A3P Biomedical involves risk, just like other investments in unlisted shares. The company operates in the medical technology sector, and its value may be affected by clinical evidence, regulatory requirements, commercialisation, capital requirements and demand for the company’s diagnostics. Trading in unlisted shares also generally involves lower liquidity than trading in publicly listed shares.
Where can I find A3P Biomedicals’ annual report?
A3P Biomedicals’ annual report is available under Investor Relations and Financial Reports. The company’s annual reports and other financial reports are available there for download.
How much capital has A3P Biomedical raised in total?
A3P Biomedical's capital raised is stated as SEK 535.3 million. An equity raise is a term for raising capital, while terms such as funding round, financing, or share issue are also commonly used.
Has A3P Biomedical reported a profit or a loss?
A3P Biomedical reports a negative result in the latest available information. Under Key figures, Net income for the year is stated as SEK -78,836 thousand and EBITDA as SEK -77,360 thousand. The company’s earnings trend is also shown in the Results by year graph.